Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Myriad Genetics (MYGN) over the last 16 years, with Q3 2025 value amounting to 0.51.

  • Myriad Genetics' Equity Ratio fell 2433.45% to 0.51 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.51, marking a year-over-year decrease of 2433.45%. This contributed to the annual value of 0.68 for FY2024, which is 12.49% down from last year.
  • As of Q3 2025, Myriad Genetics' Equity Ratio stood at 0.51, which was down 2433.45% from 0.57 recorded in Q2 2025.
  • Over the past 5 years, Myriad Genetics' Equity Ratio peaked at 0.78 during Q2 2022, and registered a low of 0.51 during Q3 2025.
  • In the last 5 years, Myriad Genetics' Equity Ratio had a median value of 0.68 in 2023 and averaged 0.68.
  • As far as peak fluctuations go, Myriad Genetics' Equity Ratio skyrocketed by 1801.21% in 2021, and later plummeted by 2433.45% in 2025.
  • Over the past 5 years, Myriad Genetics' Equity Ratio (Quarter) stood at 0.73 in 2021, then increased by 0.84% to 0.74 in 2022, then decreased by 7.56% to 0.68 in 2023, then fell by 0.12% to 0.68 in 2024, then decreased by 24.95% to 0.51 in 2025.
  • Its Equity Ratio was 0.51 in Q3 2025, compared to 0.57 in Q2 2025 and 0.7 in Q1 2025.